Canada - English - Health Canada

taro pharmaceuticals inc - perampanel - tablet - 8mg - perampanel 8mg

Canada - English - Health Canada

taro pharmaceuticals inc - perampanel - tablet - 10mg - perampanel 10mg

Canada - English - Health Canada

taro pharmaceuticals inc - perampanel - tablet - 12mg - perampanel 12mg

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - dichlorphenamide (unii: vvj6673mhy) (dichlorphenamide - unii:vvj6673mhy) - daranide® (dichlorphenamide tablets usp) is indicated for the treatment of elevated intraoculr pressure. daranide® (dichlorphenamide tablets usp) is contraindicated in hepatic insufficiency. daranide® is contraindicated in renal failure, adrenocortical insufficiency, hyperchloremic acidosis, or in conditions in which serum levels of sodium or potassium are depressed. daranide® should not be used in patients with severe pulmonary obstruction who are unable to increase their alveolar ventilation since their acidosis may be increased. daranide® is contraindicated in patients who are hypersensitive to this product. pregnancy category c. dichlorphenamide has been shown to be teratogenic in the rat (skeletal anomalies) when given in doses 100 times the human dose. there are no adequate and well-controlled studies in pregnant women. daranide® (dichlorphenamide tablets usp) should not be used in women of childbearing age or in pregnancy, especially during the first trimester, unless the potential benefits

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 4 mg - ondansetron is indicated for the prevention of nausea and vomiting associated with: - highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2 . - initial and repeat courses of moderately emetogenic cancer chemotherapy. - radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting. ondansetron is contraindicated in patients: - known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation [see adverse reactions (6.2)] . - receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness. risk summary available data do not reliably inform the association of ondansetron and adverse fetal outcomes. published epidemiological studies on the association between ondansetron and fetal outcomes have reported inconsistent findings and

Canada - English - Health Canada

taro pharmaceuticals inc - fluconazole - tablet - 50mg - fluconazole 50mg - azoles

Canada - English - Health Canada

taro pharmaceuticals inc - fluconazole - tablet - 100mg - fluconazole 100mg - azoles

Canada - English - Health Canada

taro pharmaceuticals inc - fluconazole - tablet - 200mg - fluconazole 200mg - azoles

Canada - English - Health Canada

taro pharmaceuticals inc - gabapentin - capsule - 100mg - gabapentin 100mg - miscellaneous anticonvulsants

Canada - English - Health Canada

taro pharmaceuticals inc - phenytoin - suspension - 125mg - phenytoin 125mg - hydantoins